

Elizabeth R Plimack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6041082/publications.pdf>

Version: 2024-02-01

175
papers

31,736
citations

17429

63
h-index

4988

167
g-index

178
all docs

178
docs citations

178
times ranked

27414
citing authors

#	ARTICLE	IF	CITATIONS
1	Placing Adjuvant Chemotherapy in the Evolving Paradigm of Perioperative Therapy for Bladder Cancer. <i>European Urology</i> , 2022, 81, 62-63.	0.9	0
2	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	0.9	33
3	Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 71-90.	2.3	248
4	A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 735-740.	2.0	12
5	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103
6	Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A). <i>Journal of Clinical Oncology</i> , 2022, 40, 2913-2923.	0.8	40
7	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	3.2	21
8	Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHARTED E3805. <i>Prostate</i> , 2022, 82, 1176-1185.	1.2	2
9	A Seat at the Table: The Correlation Between Female Authorship and Urology Journal Editorial Board Membership. <i>European Urology Focus</i> , 2022, 8, 1751-1757.	1.6	6
10	Molecular Profiling of Exceptional Responders to Cancer Therapy. <i>Oncologist</i> , 2021, 26, 186-195.	1.9	15
11	Identification of a Synthetic Lethal Relationship between Nucleotide Excision Repair Deficiency and Irofulven Sensitivity in Urothelial Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2011-2022.	3.2	19
12	Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trial. <i>European Journal of Cancer</i> , 2021, 145, 1-10.	1.3	17
13	Genetic Differences Between Bladder and Upper Urinary Tract Carcinoma: Implications for Therapy. <i>European Urology Oncology</i> , 2021, 4, 170-179.	2.6	28
14	Assessing Contemporary Trends in Female Speakership within Urologic Oncology. <i>Urology</i> , 2021, 150, 41-46.	0.5	11
15	Inhibition of hypoxia-inducible factor-2 α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. <i>Nature Medicine</i> , 2021, 27, 802-805.	15.2	151
16	Safety of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer and malignant ureteric obstruction. <i>BJU International</i> , 2021, , .	1.3	1
17	Treatment of Metastatic Urothelial Carcinoma After Previous Cisplatin-based Chemotherapy for Localized Disease: A Retrospective Comparison of Different Chemotherapy Regimens. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 125-134.	0.9	4
18	Cystoscopy and Systematic Bladder Tissue Sampling in Predicting pT0 Bladder Cancer: A Prospective Trial. <i>Journal of Urology</i> , 2021, 205, 1605-1611.	0.2	11

#	ARTICLE	IF	CITATIONS
19	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of urothelial cancer. , 2021, 9, e002552.		16
20	Systemic Therapy for Advanced Nonâ€“clear-Cell Renal Cell Carcinoma: Slow but Definite Progress. European Urology, 2021, 80, 171-173.	0.9	5
21	Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance). Journal of Clinical Oncology, 2021, 39, 2486-2496.	0.8	26
22	Refining neoadjuvant therapy clinical trial design for muscle-invasive bladder cancer before cystectomy: a joint US Food and Drug Administration and Bladder Cancer Advocacy Network workshop. Nature Reviews Urology, 2021, , .	1.9	6
23	The European Urology Commitment to Gender Equity and Diversity: Expanding Cognitive Diversity through Inclusivity at the Podium. European Urology, 2021, 80, 450-453.	0.9	11
24	Role of immunotherapy in localized muscle invasive urothelial cancer. Therapeutic Advances in Medical Oncology, 2021, 13, 17588359211045858.	1.4	4
25	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. Clinical Cancer Research, 2021, 27, 6687-6695.	3.2	25
26	Molecular Genetic Determinants of Shorter Time on Active Surveillance in a Prospective Phase 2 Clinical Trial in Metastatic Renal Cell Carcinoma. European Urology, 2021, , .	0.9	9
27	Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. European Urology Oncology, 2020, 3, 671-679.	2.6	11
28	First-line Immunotherapy in Metastatic Urothelial Carcinoma. European Urology Focus, 2020, 6, 45-47.	1.6	3
29	Eligibility and Radiologic Assessment for Adjuvant Clinical Trials in Kidney Cancer. JAMA Oncology, 2020, 6, 133.	3.4	11
30	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 1563-1573.	5.1	466
31	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
32	Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with longâ€“term followâ€“up of the randomized, openâ€“label, phase 3 CheckMate 025 trial. Cancer, 2020, 126, 4156-4167.	2.0	201
33	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	2.0	343
34	Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHARTED Trial. European Urology Oncology, 2020, 3, 717-724.	2.6	15
35	Angiogenic and Immune-Related Biomarkers and Outcomes Following Axitinib/Pembrolizumab Treatment in Patients with Advanced Renal Cell Carcinoma. Clinical Cancer Research, 2020, 26, 5598-5608.	3.2	13
36	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2020, 38, 2658-2666.	0.8	186

#	ARTICLE	IF	CITATIONS
37	Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. <i>European Urology Oncology</i> , 2020, 3, 544-547.	2.6	52
38	Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status. <i>European Urology Oncology</i> , 2020, 3, 351-359.	2.6	31
39	Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma. <i>Journal of Urology</i> , 2020, 203, 690-698.	0.2	76
40	Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5001-5001.	0.8	50
41	Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 329-354.	2.3	383
42	NCCN Guidelines Insights: Kidney Cancer, Version 1.2021. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1160-1170.	2.3	163
43	Integration of Immunotherapy Into the Treatment of Advanced Urothelial Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 355-361.	2.3	8
44	Reply by Authors. <i>Journal of Urology</i> , 2020, 203, 697-698.	0.2	0
45	<i>ERCC2</i> Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 977-988.	3.2	104
46	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	5.1	594
47	Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. <i>European Urology</i> , 2019, 76, 425-429.	0.9	15
48	Fibroblast Growth Factor Receptor 3 Alterations and Response to PD-1/PD-L1 Blockade in Patients with Metastatic Urothelial Cancer. <i>European Urology</i> , 2019, 76, 599-603.	0.9	95
49	Biomarkers for neoadjuvant checkpoint blockade response in urothelial cancer. <i>Nature Medicine</i> , 2019, 25, 1650-1651.	15.2	7
50	Tumor downstaging as an intermediate endpoint to assess the activity of neoadjuvant systemic therapy in patients with muscle-invasive bladder cancer. <i>Cancer</i> , 2019, 125, 3155-3163.	2.0	32
51	A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. <i>Cancer</i> , 2019, 125, 2400-2408.	2.0	18
52	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	13.9	2,319
53	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	5.1	124
54	Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2a€“4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. <i>European Urology Oncology</i> , 2019, 2, 248-256.	2.6	11

#	ARTICLE	IF	CITATIONS
55	Clinical implications of molecular subtyping in bladder cancer. <i>Current Opinion in Urology</i> , 2019, 29, 350-356.	0.9	20
56	Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. <i>European Urology Oncology</i> , 2019, 2, 355-364.	2.6	25
57	First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer. <i>Oncologist</i> , 2019, 24, e930-e942.	1.9	41
58	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	1.9	10
59	Efficacy of Split Schedule Versus Conventional Schedule Neoadjuvant Cisplatin-Based Chemotherapy for Muscle-Invasive Bladder Cancer. <i>Oncologist</i> , 2019, 24, 688-690.	1.9	15
60	KEYNOTE-052: Phase 2 study evaluating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC)â€™ Updated response and survival results.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4546-4546.	0.8	19
61	Pembrolizumab plus ipilimumab or pegylated interferon alfa-2b for patients with melanoma or renal cell carcinoma: take new drugs but keep the old?. <i>Annals of Translational Medicine</i> , 2019, 7, S95-S95.	0.7	2
62	Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 479-505.	2.3	943
63	NCCN Guidelines Insights: Kidney Cancer, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1278-1285.	2.3	185
64	Recent developments in the treatment of advanced bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 109-114.	0.8	34
65	Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 405-415.	5.1	305
66	Chemoimmunotherapy in Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2018, 73, 760-762.	0.9	0
67	Immunotherapy for metastatic urothelial carcinoma: putting the brakes on releasing the brake. <i>Immunotherapy</i> , 2018, 10, 423-425.	1.0	1
68	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
69	Bone Metastases as the Only Metastatic Site in Patients With Urothelial Carcinoma: Focus on a Special Patient Population. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e483-e490.	0.9	12
70	Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-382.	0.8	75
71	Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 1088-1095.	0.8	72
72	Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHARTED Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 1080-1087.	0.8	702

#	ARTICLE	IF	CITATIONS
73	Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions. <i>Current Urology Reports</i> , 2018, 19, 109.	1.0	47
74	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018, 8, 463.	1.3	27
75	Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. <i>Science</i> , 2018, 362, .	6.0	1,575
76	Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. , 2018, 6, 109.		151
77	NCCN Guidelines Insights: Bladder Cancer, Version 5.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 1041-1053.	2.3	171
78	Neoadjuvant Dose-dense Gemcitabine and Cisplatin in Muscle-Invasive Bladder Cancer: Results of a Phase 2 Trial. <i>European Urology Oncology</i> , 2018, 1, 54-60.	2.6	26
79	Role of Checkpoint Inhibition in Localized Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 190-198.	2.6	26
80	Molecular and Clinical Insights into the Role and Significance of Mutated DNA Repair Genes in Bladder Cancer. <i>Bladder Cancer</i> , 2018, 4, 9-18.	0.2	18
81	Approved checkpoint inhibitors in bladder cancer: which drug should be used when?. <i>Therapeutic Advances in Medical Oncology</i> , 2018, 10, 175883591878831.	1.4	49
82	Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis. <i>European Urology</i> , 2018, 74, 387-393.	0.9	41
83	Updated efficacy and safety of KEYNOTE-052: A single-arm phase 2 study investigating first-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4524-4524.	0.8	36
84	Provider and patient burdens of obtaining oral anticancer medications. <i>American Journal of Managed Care</i> , 2018, 24, e128-e133.	0.8	10
85	Evolving landscape of the treatment of metastatic clear cell renal cell carcinoma. <i>Clinical Advances in Hematology and Oncology</i> , 2018, 16, 677-686.	0.3	4
86	Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. <i>Lancet Oncology</i> , The, 2017, 18, 212-220.	5.1	307
87	Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2017, 18, 312-322.	5.1	1,388
88	Checkpoint Inhibitors for the Treatment of Renal Cell Carcinoma. <i>Current Treatment Options in Oncology</i> , 2017, 18, 7.	1.3	46
89	CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 962-971.	0.9	199
90	Treatment Beyond Progression in Patients with Advanced Renal Cell Carcinoma Treated with Nivolumab in CheckMate 025. <i>European Urology</i> , 2017, 72, 368-376.	0.9	209

#	ARTICLE	IF	CITATIONS
91	Endocrine-related adverse events associated with immune checkpoint blockade and expert insights on their management. <i>Cancer Treatment Reviews</i> , 2017, 58, 70-76.	3.4	228
92	Integrating Immunotherapy Into the Management of Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 841-847.	2.3	8
93	The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2017, 23, 3557-3565.	3.2	19
94	A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with <i>FGFR3</i> Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157. <i>Clinical Cancer Research</i> , 2017, 23, 3003-3011.	3.2	59
95	Management and outcomes of patients with renal medullary carcinoma: a multicentre collaborative study. <i>BJU International</i> , 2017, 120, 782-792.	1.3	68
96	Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1240-1267.	2.3	220
97	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2017, 18, 1483-1492.	5.1	1,034
98	Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 804-834.	2.3	443
99	Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors. <i>Oncologist</i> , 2017, 22, 1232-1237.	1.9	109
100	Small-Cell Carcinoma of the Bladder: 20-Year Single-Institution Retrospective Review. <i>Clinical Genitourinary Cancer</i> , 2017, 15, e337-e343.	0.9	18
101	Distress and Financial Distress in Adults With Cancer: An Age-Based Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1224-1233.	2.3	38
102	Mutational patterns in chemotherapy resistant muscle-invasive bladder cancer. <i>Nature Communications</i> , 2017, 8, 2193.	5.8	99
103	Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107. <i>Kidney Cancer</i> , 2017, 1, 123-132.	0.2	31
104	Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 3851-3858.	0.8	384
105	Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 2993-3001.	0.8	145
106	Bending the Curve of Advanced Urothelial Carcinoma. <i>Journal of Oncology Practice</i> , 2017, 13, 319-320.	2.5	0
107	Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 4502-4502.	0.8	49
108	TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy. <i>Oncotarget</i> , 2016, 7, 68206-68228.	0.8	8

#	ARTICLE	IF	CITATIONS
109	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	2.3	93
110	Prostate Cancer, Version 1.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 19-30.	2.3	544
111	Relationships Among Financial Distress, Emotional Distress, and Overall Distress in Insured Patients With Cancer. Journal of Oncology Practice, 2016, 12, e755-e764.	2.5	83
112	Second-generation Androgen Receptor-Targeted Therapies in Nonmetastatic Castration-resistant Prostate Cancer: Effective Early Intervention or Intervening Too Early?. European Urology, 2016, 70, 971-973.	0.9	5
113	Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression. JAMA Oncology, 2016, 2, 1179.	3.4	154
114	Targeted Therapy for Metastatic Urothelial Cancer: A Work in Progress. Journal of Clinical Oncology, 2016, 34, 2088-2092.	0.8	8
115	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2016, 22, 5461-5471.	3.2	234
116	Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial. Lancet Oncology, 2016, 17, 1317-1324.	5.1	200
117	Advanced small cell carcinoma of the bladder: clinical characteristics, treatment patterns and outcomes in 960 patients and comparison with urothelial carcinoma. Cancer Medicine, 2016, 5, 192-199.	1.3	32
118	Emerging role of immunotherapy in urothelial carcinoma—Advanced disease. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 538-547.	0.8	41
119	National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. Journal of Clinical Oncology, 2016, 34, 3346-3348.	0.8	6
120	Checkpoint inhibitors for renal cell carcinoma: current landscape and future directions. Immunotherapy, 2016, 8, 785-798.	1.0	7
121	Systemic therapy for bladder cancer finally comes into a new age. Future Oncology, 2016, 12, 2227-2242.	1.1	6
122	Circulating biomarkers to guide systemic therapy for urothelial carcinoma. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 502-509.	0.8	8
123	Fox Chase Cancer Center's Genitourinary Division: a national resource for research, innovation and patient care. Future Oncology, 2016, 12, 887-891.	1.1	0
124	Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial Cancer. Clinical Genitourinary Cancer, 2016, 14, 511-517.	0.9	5
125	Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma. JAMA Oncology, 2016, 2, 1094.	3.4	205
126	Kidney Cancer, Version 3.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 151-159.	2.3	198

#	ARTICLE	IF	CITATIONS
127	Measuring the Efficacy and Value of Urothelial Cancer Urinary Biomarkers. <i>Annals of Internal Medicine</i> , 2015, 163, 954-955.	2.0	2
128	Testicular Cancer, Version 2.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 772-799.	2.3	98
129	Hypoalbuminaemia is associated with mortality in patients undergoing cytoreductive nephrectomy. <i>BJU International</i> , 2015, 116, 351-357.	1.3	29
130	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. <i>Journal of Urology</i> , 2015, 194, 297-303.	0.2	80
131	Corticosteroids and Prostate Cancer: Friend or Foe?. <i>European Urology</i> , 2015, 67, 874-875.	0.9	4
132	A Review of Interventional Clinical Trials in Renal Cell Carcinoma: A Status Report From the ClinicalTrials.gov WebSite. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 142-149.	0.9	7
133	Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2015, 68, 959-967.	0.9	395
134	Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors. <i>Investigational New Drugs</i> , 2015, 33, 1040-1047.	1.2	50
135	Evaluating toxicity from definitive radiation therapy for prostate cancer in men with inflammatory bowel disease: Patient selection and dosimetric parameters with modern treatment techniques. <i>Practical Radiation Oncology</i> , 2015, 5, e215-e222.	1.1	21
136	Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1803-1813.	13.9	4,889
137	Targeting Signaling Transduction Pathways in Bladder Cancer. <i>Current Oncology Reports</i> , 2015, 17, 58.	1.8	37
138	Muscle-invasive urothelial bladder cancer: an update on systemic therapy. <i>Therapeutic Advances in Urology</i> , 2015, 7, 312-330.	0.9	34
139	Osteoclast Inhibitors in Advanced Prostate Cancer: Does the Benefit Extend Beyond Skeletal-Related Events?. <i>European Urology</i> , 2015, 68, 578-580.	0.9	0
140	Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1430-1437.	0.8	914
141	Pembrolizumab (MK-3475) for advanced urothelial cancer: Updated results and biomarker analysis from KEYNOTE-012.. <i>Journal of Clinical Oncology</i> , 2015, 33, 4502-4502.	0.8	64
142	Follow-Up Management of Patients With Testicular Cancer: A Multidisciplinary Consensus-Based Approach. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 811-822.	2.3	9
143	A Phase I Study of Temsirolimus and Bryostatins in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma. <i>Oncologist</i> , 2014, 19, 354-355.	1.9	20
144	Reply to D. Pouessel et al, J.B. Aragon-Ching, and B.A. Adesunloye. <i>Journal of Clinical Oncology</i> , 2014, 32, 4171-4172.	0.8	1

#	ARTICLE	IF	CITATIONS
145	Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGF1 and IGFII, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 4747-4757.	3.2	50
146	Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy. <i>Cancer Cell</i> , 2014, 25, 152-165.	7.7	1,358
147	Micropapillary bladder cancer: Current treatment patterns and review of the literature. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 826-832.	0.8	48
148	A phase I study of decitabine with pegylated interferon α -2b in advanced melanoma: impact on DNA methylation and lymphocyte populations. <i>Investigational New Drugs</i> , 2014, 32, 969-975.	1.2	12
149	PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection. <i>Cancer Immunology Research</i> , 2014, 2, 320-331.	1.6	138
150	Coexisting Hybrid Malignancy in a Solitary Sporadic Solid Benign Renal Mass: Implications for Treating Patients Following Renal Biopsy. <i>Journal of Urology</i> , 2014, 191, 296-300.	0.2	49
151	Accelerated Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Is Safe, Effective, and Efficient Neoadjuvant Treatment for Muscle-Invasive Bladder Cancer: Results of a Multicenter Phase II Study With Molecular Correlates of Response and Toxicity. <i>Journal of Clinical Oncology</i> , 2014, 32, 1895-1901.	0.8	241
152	Prostate Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 686-718.	2.3	294
153	Kidney Cancer, Version 2.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2014, 12, 175-182.	2.3	56
154	Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5010-5010.	0.8	154
155	Immune checkpoint blockade as a novel immunotherapeutic strategy for renal cell carcinoma: a review of clinical trials. <i>Discovery Medicine</i> , 2014, 18, 341-50.	0.5	17
156	Reply to S. Buti and S. Culine. <i>Journal of Clinical Oncology</i> , 2013, 31, 1615-1616.	0.8	0
157	AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors. <i>Oncologist</i> , 2013, 18, 819-820.	1.9	96
158	Prostate Cancer, Version 1.2014. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 1471-1479.	2.3	82
159	Penile Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 594-615.	2.3	149
160	Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 446-475.	2.3	309
161	Optimizing Systemic Therapy for Bladder Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 793-804.	2.3	23
162	Phase II Trial of Cetuximab With or Without Paclitaxel in Patients With Advanced Urothelial Tract Carcinoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 3545-3551.	0.8	115

#	ARTICLE	IF	CITATIONS
163	Potential role of 124I-girentuximab in the presurgical diagnosis of clear-cell renal cell cancer. <i>Biologics: Targets and Therapy</i> , 2012, 6, 395.	3.0	14
164	Prostate Cancer, Version 3.2012 Featured Updates to the NCCN Guidelines. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1081-1087.	2.3	208
165	A Phase 2 Trial of Sunitinib in Patients with Advanced Non-clear Cell Renal Cell Carcinoma. <i>European Urology</i> , 2012, 62, 1013-1019.	0.9	139
166	Clinical Stage T1 Micropapillary Urothelial Carcinoma Presenting With Metastasis to the Pancreas. <i>Urology</i> , 2012, 79, e9-e10.	0.5	7
167	A Wealth of New Options: A Case Presentation of the Management of Castration-Recurrent Prostate Cancer. <i>Seminars in Oncology</i> , 2012, 39, 1-8.	0.8	5
168	Prolonged natural progression from localized to symptomatic renal cell carcinoma. <i>Canadian Journal of Urology</i> , 2012, 19, 6578-80.	0.0	1
169	Baseline Renal Function Status Limits Patient Eligibility to Receive Perioperative Chemotherapy for Invasive Bladder Cancer and Is Minimally Affected by Radical Cystectomy. <i>Urology</i> , 2011, 77, 160-165.	0.5	63
170	Selecting Targeted Therapies for Patients With Renal Cell Carcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2011, 9, 997-1006.	2.3	9
171	Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. <i>BJU International</i> , 2011, 107, 58-62.	1.3	46
172	Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon. <i>Cancer</i> , 2009, 115, 1859-1866.	2.0	30
173	Decitabine and its role in the treatment of hematopoietic malignancies. <i>Leukemia and Lymphoma</i> , 2007, 48, 1472-1481.	0.6	101
174	Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study. <i>Gynecologic Oncology</i> , 2006, 100, 324-329.	0.6	10
175	Biweekly 72-Hour 9-Aminocamptothecin Infusion As Second-Line Therapy for Ovarian Carcinoma: Phase II Study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group. <i>Journal of Clinical Oncology</i> , 2004, 22, 120-126.	0.8	17